Neurodegenerative and Dementia Diseases
Neurodegenerative and dementia diseases are a family of chronic, progressive disorders in which neurons in the brain or spinal cord are gradually lost, producing accumulating deficits in cognition, movement, or both. They include Alzheimer disease and other dementias, Parkinson disease, frontotemporal dementia, amyotrophic lateral sclerosis, and multiple sclerosis, and together they account for a large and rising share of the global neurological disease burden as populations age.
Definition
Neurodegenerative diseases are disorders characterised by the progressive structural and functional loss of neurons, frequently associated with the misfolding and aggregation of specific proteins (such as amyloid-beta, tau, alpha-synuclein, or TDP-43) and leading to clinical syndromes of dementia, movement impairment, or motor-neuron failure.
Scope
This area orients the reader to the shared features of neurodegenerative disease as a class: selective vulnerability of neuronal populations, abnormal protein aggregation, progressive and largely irreversible course, and stereotyped spread of pathology through connected brain regions. It then frames the individual entities authored as topics beneath it. It is a reference overview of how this disease family is conceptualised, not a clinical management guide.
Sub-topics
Core questions
- What makes particular neuronal populations selectively vulnerable in each disease?
- How do misfolded proteins aggregate and propagate through neural networks?
- How do distinct molecular pathologies converge on overlapping clinical syndromes?
- How can biomarkers define these diseases biologically before or alongside symptoms?
Key concepts
- Selective neuronal vulnerability
- Proteinopathy
- Amyloid-beta, tau, alpha-synuclein, and TDP-43
- Progressive and irreversible course
- Neuroinflammation and glial response
- Biomarker-based disease definition
- Mixed pathology in older brains
Key theories
- Protein misfolding and aggregation
- Many neurodegenerative diseases are unified by the accumulation of specific misfolded proteins into insoluble aggregates, allowing them to be grouped as proteinopathies (for example amyloidopathies, tauopathies, synucleinopathies, and TDP-43 proteinopathies).
- Prion-like propagation
- Pathological protein assemblies can template the misfolding of normal protein and spread along anatomically connected pathways, offering a framework for the stereotyped progression of pathology seen across several of these diseases.
Mechanisms
Across this family, disease tends to begin with the misfolding and aggregation of a characteristic protein within vulnerable neurons, accompanied by synaptic dysfunction, impaired protein clearance, mitochondrial and oxidative stress, and a sustained glial inflammatory response. Pathology typically begins focally and spreads in a stereotyped pattern through connected circuits, which helps explain why clinical syndromes evolve predictably over years. Overlap is common: distinct molecular pathologies can produce similar syndromes, the same protein can cause more than one disease, and older brains frequently harbour mixed pathologies, blurring boundaries that clinical classification draws sharply (Dugger & Dickson, 2017; Neumann et al., 2006).
Clinical relevance
Understanding neurodegenerative disease as a class informs how clinicians and researchers interpret overlapping syndromes, combine clinical assessment with imaging and fluid biomarkers, and reason about prognosis. This overview describes how the disease family is understood and studied; it is not a basis for individual diagnosis or treatment decisions.
Epidemiology
Neurodegenerative and related neurological disorders are among the leading global contributors to disability and a major and growing cause of death, with burden rising substantially as populations age. Dementias and movement disorders dominate this burden in absolute terms, and the Global Burden of Disease analyses document a marked increase in cases over recent decades driven largely by demographic change (GBD 2016 Neurology Collaborators, 2019).
History
The recognition of distinct neurodegenerative diseases unfolded over more than a century, from nineteenth- and early twentieth-century clinicopathological descriptions to the molecular era. The identification of the proteins that aggregate in each disorder, and the realisation that these proteins can spread through the nervous system in stereotyped patterns, reframed the field around shared mechanisms of proteinopathy and propagation while preserving the clinical distinctions between entities (Dugger & Dickson, 2017).
Debates
- Should these diseases be classified clinically or molecularly?
- Because distinct proteinopathies can cause overlapping syndromes and a single syndrome can have several underlying pathologies, there is ongoing tension between syndrome-based clinical classification and biomarker- or pathology-based molecular classification.
Key figures
- Alois Alzheimer
- James Parkinson
- Heiko Braak
- Dennis Dickson
- Manuela Neumann
Related topics
Seminal works
- dugger-dickson-2017
- neumann-2006
- gbd-neurology-2019
Frequently asked questions
- What links the different neurodegenerative diseases together?
- Most share progressive neuronal loss tied to the misfolding and aggregation of specific proteins, a slow and largely irreversible course, and a tendency for pathology to spread through connected brain regions, even though each disease targets different cells and produces different symptoms.
- Is dementia the same as neurodegenerative disease?
- No. Dementia is a clinical syndrome of acquired cognitive decline that has many causes; neurodegenerative diseases such as Alzheimer disease are common causes of dementia, but some neurodegenerative diseases (for example amyotrophic lateral sclerosis) primarily affect movement rather than cognition.